BlackRock’s bluebird bio BLUE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-697,973
| Closed | -$3.41M | – | 5467 |
|
|
2025
Q1 | $3.41M | Sell |
697,973
-10,696
| -2% | -$64.3K | ﹤0.01% | 3796 |
|
|
2024
Q4 | $5.91M | Sell |
708,669
-63,519
| -8% | -$555K | ﹤0.01% | 3654 |
|
|
2024
Q3 | $8.02M | Buy |
772,188
+77
| +0% | +$1.28K | ﹤0.01% | 3514 |
|
|
2024
Q2 | $15.2M | Buy |
772,111
+13,183
| +2% | +$264K | ﹤0.01% | 3146 |
|
|
2024
Q1 | $19.4M | Buy |
758,928
+309,778
| +69% | +$7.94M | ﹤0.01% | 3008 |
|
|
2023
Q4 | $12.4M | Buy |
449,150
+7,729
| +2% | +$471K | ﹤0.01% | 3278 |
|
|
2023
Q3 | $26.8M | Buy |
441,421
+1,785
| +0.4% | +$125K | ﹤0.01% | 2771 |
|
|
2023
Q2 | $28.9M | Sell |
439,636
-7,663
| -2% | -$561K | ﹤0.01% | 2798 |
|
|
2023
Q1 | $28.4M | Buy |
447,299
+78,866
| +21% | +$9.01M | ﹤0.01% | 2788 |
|
|
2022
Q4 | $51M | Buy |
368,433
+23,484
| +7% | +$3.31M | ﹤0.01% | 2453 |
|
|
2022
Q3 | $43.7M | Buy |
344,949
+54,282
| +19% | +$6.14M | ﹤0.01% | 2543 |
|
|
2022
Q2 | $24.1M | Sell |
290,667
-1,189
| -0.4% | -$92.2K | ﹤0.01% | 2992 |
|
|
2022
Q1 | $28.3M | Sell |
291,856
-3,744
| -1% | -$494K | ﹤0.01% | 2947 |
|
|
2021
Q4 | $59.1M | Sell |
295,600
-149,822
| -34% | -$35.4M | ﹤0.01% | 2539 |
|
|
2021
Q3 | $110M | Sell |
445,422
-10,760
| -2% | -$3.08M | ﹤0.01% | 2152 |
|
|
2021
Q2 | $189M | Buy |
456,182
+148,345
| +48% | +$58.8M | 0.01% | 1808 |
|
|
2021
Q1 | $120M | Buy |
307,837
+9,718
| +3% | +$4.79M | ﹤0.01% | 2081 |
|
|
2020
Q4 | $167M | Buy |
298,119
+9,978
| +3% | +$6.32M | 0.01% | 1747 |
|
|
2020
Q3 | $201M | Sell |
288,141
-20,123
| -7% | -$15.7M | 0.01% | 1385 |
|
|
2020
Q2 | $244M | Buy |
308,264
+85,749
| +39% | +$64.7M | 0.01% | 1220 |
|
|
2020
Q1 | $132M | Sell |
222,515
-3,321
| -1% | -$3.24M | 0.01% | 1457 |
|
|
2019
Q4 | $257M | Sell |
225,836
-445
| -0.2% | -$484K | 0.01% | 1291 |
|
|
2019
Q3 | $269M | Buy |
226,281
+2,208
| +1% | +$3.37M | 0.01% | 1185 |
|
|
2019
Q2 | $369M | Sell |
224,073
-6,030
| -3% | -$10.4M | 0.02% | 981 |
|
|
2019
Q1 | $469M | Sell |
230,103
-427
| -0.2% | -$752K | 0.02% | 771 |
|
|
2018
Q4 | $296M | Buy |
230,530
+2,629
| +1% | +$4.03M | 0.02% | 1010 |
|
|
2018
Q3 | $431M | Buy |
227,901
+16,745
| +8% | +$34.6M | 0.02% | 847 |
|
|
2018
Q2 | $429M | Sell |
211,156
-87,466
| -29% | -$199M | 0.02% | 835 |
|
|
2018
Q1 | $660M | Buy |
298,622
+2,840
| +1% | +$7.22M | 0.03% | 569 |
|
|
2017
Q4 | $682M | Buy |
295,782
+17,887
| +6% | +$36.3M | 0.03% | 551 |
|
|
2017
Q3 | $494M | Buy |
277,895
+21,566
| +8% | +$30.1M | 0.02% | 673 |
|
|
2017
Q2 | $349M | Buy |
256,329
+10,664
| +4% | +$12.9M | 0.02% | 862 |
|
|
2017
Q1 | $289M | Buy |
245,665
+245,120
| +44,976% | +$250M | 0.02% | 1003 |
|
|
2016
Q4 | $436K | Sell |
545
-1,319
| -71% | -$1.05M | ﹤0.01% | 1763 |
|
|
2016
Q3 | $1.64M | Buy |
1,864
+1,313
| +238% | +$951K | ﹤0.01% | 1287 |
|
|
2016
Q2 | $309K | Buy |
551
+198
| +56% | +$112K | ﹤0.01% | 1871 |
|
|
2016
Q1 | $194K | Buy |
353
+273
| +341% | +$168K | ﹤0.01% | 1745 |
|
|
2015
Q4 | $67K | Buy |
80
+6
| +8% | +$5.99K | ﹤0.01% | 1907 |
|
|
2015
Q3 | $82K | Buy |
74
+5
| +7% | +$9.12K | ﹤0.01% | 1769 |
|
|
2015
Q2 | $150K | Buy |
69
+20
| +41% | +$40.7K | ﹤0.01% | 1727 |
|
|
2015
Q1 | $77K | Sell |
49
-11
| -18% | -$14.5K | ﹤0.01% | 1823 |
|
|
2014
Q4 | $71K | Sell |
60
-2,181
| -97% | -$1.46M | ﹤0.01% | 1823 |
|
|
2014
Q3 | $1.04M | Buy |
2,241
+2,206
| +6,303% | +$1.02M | ﹤0.01% | 1202 |
|
|
2014
Q2 | $17K | Buy |
35
+18
| +106% | +$5.77K | ﹤0.01% | 2464 |
|
|
2014
Q1 | $5K | Sell |
17
-2,851
| -99% | -$864K | ﹤0.01% | 3040 |
|
|
2013
Q4 | $779K | Buy |
2,868
+2,857
| +25,973% | +$798K | ﹤0.01% | 1233 |
|
|
2013
Q3 | $4K | Buy |
+11
| New | +$4.08K | ﹤0.01% | 3033 |
|
Other funds holding BLUE
BlackRock's BLUE Position: Q2 2025 in Review
BlackRock sold out of bluebird bio (BLUE) in Q2 2025, closing a stake of 697,973 shares — an estimated $3.41M sold.
BlackRock first reported a position in BLUE in Q3 2013 and held it in 47 quarters. The position peaked at $682M in Q4 2017. 3 funds tracked by Wall St. Rank hold BLUE as of Q2 2025.
- BlackRock reported no remaining bluebird bio position as of Q2 2025 after selling out during the quarter.
- BlackRock sold 697,973 bluebird bio shares in Q2 2025, an estimated $3.41M.
- BlackRock first reported a position in bluebird bio in Q3 2013 and held it in 47 quarters.
- BlackRock's bluebird bio position peaked at $682M in Q4 2017.
- 3 funds tracked by Wall St. Rank held bluebird bio as of Q2 2025.
Based on BlackRock's 13F filing for Q2 2025, filed 12 Aug 2025.